Shanghai Hile Bio-Technology (603718) Stock Overview
Researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
603718 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shanghai Hile Bio-Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.97 |
| 52 Week High | CN¥8.66 |
| 52 Week Low | CN¥6.18 |
| Beta | 0.39 |
| 1 Month Change | 0% |
| 3 Month Change | -5.04% |
| 1 Year Change | -14.27% |
| 3 Year Change | -33.62% |
| 5 Year Change | -56.30% |
| Change since IPO | 63.41% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Shanghai Hile Bio-Technology (SHSE:603718) Use Debt?
Dec 17
Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) 28% Share Price Surge Not Quite Adding Up
Nov 14Investor Optimism Abounds Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) But Growth Is Lacking
Sep 30There May Be Some Bright Spots In Shanghai Hile Bio-Technology's (SHSE:603718) Earnings
May 06Earnings Not Telling The Story For Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718)
Apr 29Shareholder Returns
| 603718 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.0% | 0.9% | -1.1% |
| 1Y | -14.3% | 20.6% | 23.0% |
Return vs Industry: 603718 underperformed the CN Pharmaceuticals industry which returned 20.6% over the past year.
Return vs Market: 603718 underperformed the CN Market which returned 23% over the past year.
Price Volatility
| 603718 volatility | |
|---|---|
| 603718 Average Weekly Movement | 2.0% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 603718 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603718's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 366 | Benyi Han | www.hile-bio.com |
Shanghai Hile Bio-Technology Co., Ltd. researches, develops, produces, and sells veterinary biological products for livestock and poultry in China. The company offers swine fever live vaccines; trivalent inactivated vaccines for piglets; and inactivated vaccine for streptococcus suis. It also provides inactivated avian infectious rhinitis vaccines; newcastle disease and avian influenza combined inactivated vaccines; newcastle disease, infectious bronchitis, egg drop syndrome, and avian influenza quadruple inactivated vaccines; avian influenza inactivated vaccines; newcastle disease, infectious bronchitis, and avian influenza triple inactivated vaccines; avian infectious bronchitis live vaccines; avian newcastle disease, and avian infectious bronchitis combined live vaccines.
Shanghai Hile Bio-Technology Co., Ltd. Fundamentals Summary
| 603718 fundamental statistics | |
|---|---|
| Market cap | CN¥4.57b |
| Earnings (TTM) | CN¥171.34m |
| Revenue (TTM) | CN¥246.35m |
Is 603718 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603718 income statement (TTM) | |
|---|---|
| Revenue | CN¥246.35m |
| Cost of Revenue | CN¥60.34m |
| Gross Profit | CN¥186.01m |
| Other Expenses | CN¥14.67m |
| Earnings | CN¥171.34m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Nov 21, 2025
| Earnings per share (EPS) | 0.26 |
| Gross Margin | 75.51% |
| Net Profit Margin | 69.55% |
| Debt/Equity Ratio | 0.2% |
How did 603718 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/18 18:15 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Hile Bio-Technology Co., Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiao Chen | Industrial Securities Co. Ltd. |
| Yanhai Gong | SWS Research Co., Ltd. |
| Li Wu | Tianfeng Securities Brokerage Co., Ltd |